Prostate cancer is a malignancy of one of the major male sex glands, in which cells of the prostate become abnormal and start to grow uncontrollably, forming tumors.
Prostate cancer immunotherapy significantly prolongs survival in men with advanced prostate cancer. Phase 3 IMPACT trial results to be presented during late-breaking session at AUA Annual Scientific Meeting. – Sipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be presented April 28 at the American Urological Association (AUA) Annual Scientific Meeting in Chicago.
AUA counters mainstream recommendations with new best practice statement on PSA testing. New guidance stresses that PSA testing should be individualized, men should get baseline reading at age 40. – The American Urological Association (AUA) issued new clinical guidance ? which directly contrasts recent recommendations issued by other major groups ? about prostate cancer screening, asserting that the prostate-specific antigen (PSA) test should be offered to well-informed, men aged 40 years or older who have a life expectancy of at least 10 years.
Statins may exert influence on prostate cancer growth by reducing inflammation. – Cholesterol lowering drugs called statins may reduce inflammation in prostate tumors, possibly hindering cancer growth, according to a study led by investigators in the Duke Prostate Center.
American Cancer Society awards 143 research grants to investigators at 83 institutions nationwide. Grants total more than $51 million in the second of two cycles for 2009. – The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 143 national research and training grants totaling more than $51 million in the second of two grant cycles for 2009. The grants go into effect beginning July 1, 2009.
University of Leicester team examine potential of new nano technology to pave way for development of a combined diagnosis/therapeutic strategy for cancer. – A multi-disciplinary team of scientists from the University of Leicester could be potentially paving the way for the development of a powerful new strategy for both the early diagnosis and treatment of prostate cancer.
PROVENGE Significantly Prolongs Survival in Men with Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study. – Dendreon Corporation (Nasdaq: DNDN) announced that the pivotal Phase 3 IMPACT study of PROVENGE (sipuleucel-T) in men with advanced prostate cancer met its primary endpoint of improving overall survival compared to a placebo control.
Omega-3 fatty acids reduce risk of advanced prostate cancer – Omega-3 fatty acids appear protective against advanced prostate cancer, and this effect may be modified by a genetic variant in the COX-2 gene, according to a report in Clinical Cancer Research, a journal of the American Association for Cancer Research.
New international research has linked heavier drinking and prostate cancer. – An international research team from Australia, Canada and the United States found that men who drank two or more standard drinks of alcohol a day are more likely to develop prostate cancer.
Red wine vs. white? It makes no difference when it comes to breast-cancer risk – The largest study of its kind to evaluate the effect of red versus white wine on breast-cancer risk concludes that both are equal offenders when it comes to increasing breast-cancer risk.
A first degree family history of prostate cancer has no impact on the treatment outcomes of prostate cancer patients. – Family history of prostate cancer does not affect some prostate cancer patient’s treatment outcomes, revealed by researchers.
Grape seed extract kills laboratory leukemia cells, proving value of natural compounds. – An extract from grape seeds forces laboratory leukemia cells to commit cell suicide, according to researchers from the University of Kentucky. They found that within 24 hours, 76 percent of leukemia cells had died after being exposed to the extract.
Low income men more likely to be diagnosed with advanced prostate cancer – Low-income men are more likely to present with advanced prostate cancers, most likely because they don’t receive screening services shown to reduce the diagnosis of later-stage cancers, a UCLA study found.
